GURU.Markets stock price, segment price, and overall market index valuation
The company's share price VSTM
The shares of Verastem, an oncology biotech, reflect the potential of its cancer drug pipeline. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Oncology targeted therapy
Verastem, Inc. is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of oncological diseases. We classify it as part of the "Targeted Cancer Therapy" segment, which seeks targeted solutions to combat tumors. The chart below reflects the dynamics of this cutting-edge and highly competitive sector.
Broad Market Index - GURU.Markets
Verastem is an oncology company developing drugs to treat cancer by inhibiting key signaling pathways in tumor cells. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market, reflecting investor expectations.
Change in the price of a company, segment, and market as a whole per day
VSTM - Daily change in the company's share price VSTM
The daily price change of Verastem, an oncology company, reflects the extreme volatility of the biotech sector. change_co measures the reaction to clinical trial data and regulatory decisions. This metric is the basis for analyzing high-risk pharmaceutical assets on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology targeted therapy
Verastem, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with VSTM's dynamics, which depend on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Verastem is a biopharmaceutical company developing targeted therapies for cancer. Oncology is a highly volatile sector driven by clinical trial results. The chart below reflects average fluctuations in this industry, providing context for evaluating Verastem shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization VSTM
Verastem is a biotech company specializing in the development of targeted therapies for cancer treatment. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Annual dynamics of market capitalization of the market segment - Oncology targeted therapy
Verastem, Inc. is a biotech company focused on developing cancer treatments. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs inherent in the biotech sector compared to big pharma.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Verastem is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization VSTM
The performance of Verastem, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but news about the progress of clinical trials of its oncology drugs, the success of which determines its future valuation and ability to attract partners.
Monthly dynamics of market capitalization of the market segment - Oncology targeted therapy
This chart reflects the dynamics of the biotech sector, particularly oncology. For Verastem, a clinical-stage company, this is the backdrop. Its volatile movements demonstrate how investor expectations related to the results of its targeted drug trials are impacting the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Verastem is a biotech company focused on developing drugs to treat cancer by inhibiting key signaling pathways. Its value is determined by progress in clinical trials. The overall market chart provides only background information, while Verastem's performance is driven by development news, which is typical for the biotech sector.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization VSTM
Verastem, an oncology company focused on targeted therapies, exhibits high volatility. Its weekly stock price is a barometer of clinical trial news, particularly for key drugs for ovarian and pancreatic cancer.
Weekly dynamics of market capitalization of the market segment - Oncology targeted therapy
Verastem operates in the highly competitive oncology sector, where investor sentiment drives the overall trend. Any significant success or failure in the industry affects everyone's risk appetite. The chart will show whether VSTM is following the general flow of biotech speculation or whether its unique scientific news is creating its own trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Verastem, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how VSTM shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
VSTM - Market capitalization of the company VSTM
Verastem's market capitalization dynamics reflect a focused bet on fighting difficult-to-treat cancers. This biotech company's stock price reflects investor expectations for the success of its oncology drugs. Its high volatility is a direct consequence of news about clinical trials and regulatory decisions.
VSTM - Share of the company's market capitalization VSTM within the market segment - Oncology targeted therapy
Verastem Oncology is a biopharmaceutical company focused on developing drugs for the treatment of difficult-to-treat cancers. Its share of the market capitalization of its oncology segment reflects the potential of its leading developments. The chart below shows the high volatility of its valuation, dependent on clinical trial results.
Market capitalization of the market segment - Oncology targeted therapy
Verastem develops targeted cancer treatments, focusing on tumor cell signaling pathways. The chart below shows the market capitalization of the oncology sector. This is the valuation of an industry where scientific discoveries directly translate into hope for millions of patients.
Market capitalization of all companies included in a broad market index - GURU.Markets
Verastem is a biotech company focused on developing drugs for the treatment of difficult-to-treat cancers. The company's market capitalization is determined by the valuation of its lead candidate and its potential to change the standard of treatment. In the oncology field as a whole, its value represents the hope for new, effective therapies for patients with limited treatment options.
Book value capitalization of the company, segment and market as a whole
VSTM - Book value capitalization of the company VSTM
Verastem is built on scientific capital. This oncology company's book value reflects its intellectual property in the targeted drugs it develops, as well as the cash it has to finance their clinical trials. The chart below shows how the company uses its financial resources to advance its molecules through the complex R&D process.
VSTM - Share of the company's book capitalization VSTM within the market segment - Oncology targeted therapy
Verastem, a biopharmaceutical company, is focused on R&D. Its tangible assets are research laboratories. The S_BCap_Seg graph shows its small share of physical infrastructure, which is typical for innovative companies that do not yet have mass production.
Market segment balance sheet capitalization - Oncology targeted therapy
Biotechnology is a world of contrasts. The graph shows the enormous factories of pharmaceutical giants. Verastem, as a development company, has a more streamlined model. Its value lies in its intellectual property, not in the scale of production that is typical of the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Verastem develops targeted therapies to fight cancer, focusing on signaling pathways in cancer cells. The company's assets include intellectual property and clinical programs aimed at "turning off" tumors. The chart below shows the financial resources devoted to this front in the fight against cancer.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - VSTM
Verastem's balance sheet consists of cash in its accounts and the cost of its development. The market, however, doesn't value these assets, but rather the potential of its targeted therapy for treating certain types of cancer. The graph shows how much the company's hopes for success with a single key drug exceed the company's total assets combined.
Market to book capitalization ratio in a market segment - Oncology targeted therapy
Verastem, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment. Its value is entirely dependent on the success of its drugs in clinical trials. This chart shows how its market valuation is a bet on the future and is significantly disconnected from its current tangible assets.
Market to book capitalization ratio for the market as a whole
Verastem is a biotech company focused on developing cancer drugs. Its value depends almost entirely on the success of its lead drugs in clinical trials. This chart is a classic example of biotech startup valuation, where investors bet on future medical breakthroughs rather than current revenue or balance sheet assets.
Debts of the company, segment and market as a whole
VSTM - Company debts VSTM
Verastem, a biotech company focused on cancer treatment, uses debt financing to advance its drugs through late-stage clinical trials. This chart shows how the company is raising significant capital to prepare for a potential commercial launch, the most expensive stage in the life of a biotech startup.
Market segment debts - Oncology targeted therapy
Verastem Oncology is a biotech company focused on developing cancer treatments by inhibiting key signaling pathways. Funding expensive clinical trials is a key challenge for such companies. This chart shows how Verastem's debt load reflects the stage of its drug development and its capital needs to continue research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio VSTM
Verastem is a biotech company focused on developing targeted cancer therapies. Its future depends on the success of clinical trials. Debt financing allows it to continue expensive research. This graph measures financial risk: the higher the risk, the more dependent the company is on a breakthrough in its research.
Market segment debt to market segment book capitalization - Oncology targeted therapy
Verastem, a biotech company focused on developing drugs to treat difficult-to-treat cancers, compares its debt load to the overall market capitalization of the oncology sector. It shows how the clinical-stage company raises capital to fund its key research, the success of which is crucial to its future.
Debt to book value of all companies in the market
Verastem, Inc. is a biopharmaceutical company focused on developing cancer drugs. Financing lengthy and expensive clinical trials is a key challenge. This chart, reflecting the overall debt situation in the economy, provides insight into the environment in which Verastem is raising capital to advance its oncology programs.
P/E of the company, segment and market as a whole
P/E - VSTM
This metric for Verastem, Inc., a biopharmaceutical company focused on cancer treatment, illustrates the valuation of its development pipeline. Profit is not yet available. The chart does not reflect current revenue, but rather investor expectations regarding the success of its targeted drugs in clinical trials and their future commercial potential in oncology.
P/E of the market segment - Oncology targeted therapy
Verastem, Inc. is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of cancer. The company develops targeted therapies that target specific molecular pathways in tumors. This chart illustrates the average valuation in the oncology development sector, where both the potential rewards and the risks of clinical failure are high.
P/E of the market as a whole
Verastem is a biotech company focused on developing targeted therapies for cancer treatment. Its value depends on clinical trial success and regulatory approval. This chart shows the overall market temperature. Comparing it with it reveals how Verastem's valuation is detached from market realities and relies solely on hopes for a scientific breakthrough in oncology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company VSTM
For Verastem, a biotech company focused on developing cancer drugs, this chart demonstrates market expectations for its clinical programs. It reflects investor confidence in the potential of its drugs for treating difficult-to-treat tumors and their future ability to generate revenue after receiving regulatory approval.
%20P%2FE%20VSTM&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-VSTM&v=1772440687791 "Chart of the company's future (projected) P/E VSTM")
Future (projected) P/E of the market segment - Oncology targeted therapy
Verastem, Inc. is a biotechnology company focused on developing targeted therapies for the treatment of cancer. The data presented reflects profitability expectations for the entire biotech segment. Verastem's position in this context may signal how the market perceives the progress of its clinical programs and the potential of its drugs in the fight against difficult-to-treat cancers.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-targeted-therapy&v=1772440687798 "Future (projected) P/E graph of the market segment - Oncology targeted therapy")
Future (projected) P/E of the market as a whole
Verastem develops cancer treatments. For a company whose value is based on the potential of future drugs, the overall market expectations shown in this chart are of secondary importance. The key drivers are successful clinical trials and regulatory approvals.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772440687801 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit VSTM
Verastem, Inc. is a biopharmaceutical company focused on developing drugs to treat cancer by inhibiting key signaling pathways in tumor cells. This graph depicts the path from research to commercialization. A sharp increase in profits will be driven by approval and launch of their drugs, which will be the culmination of years of scientific research.
Profit of companies in the market segment - Oncology targeted therapy
Verastem, Inc. is a biotech company focused on developing targeted therapies for cancer. The profitability charts in this niche oncology segment reflect the industry's collective hopes and setbacks. For VSTM and its competitors, years of research and losses are the norm, but successful clinical trials of a single drug can lead to explosive growth for the entire field.
Overall market profit
Verastem, a biopharmaceutical company focused on cancer treatment, depends on the success of its clinical trials rather than short-term economic cycles. However, overall market conditions, reflected in this chart, play a key role in the company's ability to raise capital. A positive market trend facilitates the financing of expensive developments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company VSTM
Verastem specializes in developing targeted therapies for cancer treatment. This chart shows analysts' forecasts for future revenue, which reflect the market's confidence in the success of its drugs in clinical trials and their subsequent commercial potential. This is a financial assessment of the prospects for its oncology developments.
%20profit%20of%20the%20company%20VSTM&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-VSTM&v=1772440687806 "Graph of future (projected) profit of the company VSTM")
Future (predicted) profit of companies in the market segment - Oncology targeted therapy
Verastem, Inc. is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. Its approach involves attacking specific tumor cell signaling pathways. This chart shows revenue expectations for the oncology sector, reflecting the market's belief in the potential of personalized medicine and new approaches to cancer treatment.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-targeted-therapy&v=1772440687810 "Graph of future (predicted) profits of companies in a market segment - Oncology targeted therapy")
Future (predicted) profit of the market as a whole
Verastem, Inc. is a biopharmaceutical company focused on cancer treatment. Its success is determined by research results rather than by general economic trends. However, the presented profit forecast is important for assessing the investment climate. In a market climate of pessimism, it is becoming more difficult and expensive for biotech companies to raise capital for their developments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772440687813 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - VSTM
Verastem Oncology is focused on developing innovative drugs for the treatment of difficult-to-treat cancers. Its business model is based on bringing new drugs to market. While in clinical development, the company may not have stable revenue. The chart shows how investors assess its potential based on scientific data and future sales prospects.
P/S market segment - Oncology targeted therapy
Verastem Oncology focuses on developing drugs to treat cancer by inhibiting key signaling pathways in tumor cells. The chart shows the average revenue estimate in the biotech sector. It allows us to understand whether investor expectations for the company's targeted therapy are higher or lower than the average for the innovative oncology industry.
P/S of the market as a whole
Verastem, Inc. is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. Its future depends on the success of clinical trials. This chart, showing the average market revenue estimate, serves as a metric to understand the enormous expectations of future commercial success embedded in the company's current valuation.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company VSTM
Verastem Oncology is a biopharmaceutical company focused on developing innovative cancer treatments. This chart reflects the market's assessment of its scientific potential and clinical development, shaping the company's value based on potential future revenues from its targeted therapies in various stages of development.
%20P%2FS%20VSTM&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-VSTM&v=1772440687820 "The graph of the company's future (projected) P/S VSTM")
Future (projected) P/S of the market segment - Oncology targeted therapy
Verastem, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment. The data presented represents the average estimated future sales for oncology companies in its core competencies. This allows investors to assess how the market perceives the commercial prospects of Verastem's key drugs compared to expectations for other companies.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-targeted-therapy&v=1772440687822 "Future (projected) P/S market segment graph - Oncology targeted therapy")
Future (projected) P/S of the market as a whole
Verastem, Inc. is a biopharmaceutical company focused on cancer treatment. Its value is tied to the potential of its drugs. This graph of overall revenue expectations is of little significance to the company. Investors are focused entirely on clinical trial results, which can either create enormous value or dash expectations, regardless of market conditions.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772440687826 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales VSTM
Verastem is an oncology company developing new cancer treatments. Since its drugs are still in clinical trials, the revenue in this graph likely comes from payments from research partners. These payments, although irregular, are critical to funding further development.
Sales of companies in the market segment - Oncology targeted therapy
Verastem, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted therapies for the treatment of oncological diseases. Their approach involves targeting specific signaling pathways in cancer cells. This graph illustrates the segment's total revenue, allowing one to assess the success of the targeted therapy business.
Overall market sales
Verastem, Inc. is a biopharmaceutical company focused on developing drugs to treat cancer. This chart reflects the overall economic situation, but for VSTM, the key drivers are clinical trial results and progress in the fight against cancer. The demand for effective cancer treatments is not dependent on the stock market or GDP.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company VSTM
Verastem Oncology is a biotechnology company focused on developing drugs to treat cancer by inhibiting key signaling pathways. Future revenue is dependent on the success of clinical programs and drug approvals. This chart reflects the market's assessment of the likelihood of commercial success for its anti-cancer therapies.
%20sales%20of%20the%20company%20VSTM&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-VSTM&v=1772440687834 "Schedule of future (projected) sales of the company VSTM")
Future (projected) sales of companies in the market segment - Oncology targeted therapy
Verastem, Inc. is a biotechnology company focused on developing targeted drugs for cancer treatment. Its approach involves attacking specific tumor cell signaling pathways. This graph illustrates the outlook for the entire targeted cancer therapy industry. The company's future depends on the success of its clinical programs and the launch of its drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-targeted-therapy&v=1772440687834 "Schedule of future (projected) sales of companies in the market segment - Oncology targeted therapy")
Future (projected) sales of the market as a whole
Verastem develops drugs for the treatment of oncology. The company's success depends on investments in biotechnology and the future solvency of healthcare systems. This chart, reflecting overall economic confidence, signals investors' willingness to invest in long-term projects and the future ability of the healthcare system to pay for innovative drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772440687836 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality VSTM
Verastem is a biopharmaceutical company focused on developing cancer drugs. Being in active clinical trials, its financial performance reflects significant investments in research. This chart shows the company's financial trajectory: current R&D expenditures are an investment in future profits from potentially successful drugs.
Market segment marginality - Oncology targeted therapy
Verastem Oncology is a biotech company focused on developing drugs to treat cancer by inhibiting proteins in the RAS pathway. This chart shows the average profitability in the oncology sector. The potential of its drugs for treating difficult-to-treat cancers may allow the company to achieve significantly higher-than-average profitability in the future.
Market marginality as a whole
Verastem, Inc. is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. Its cash flows currently consist primarily of research and development expenses. This graph of total corporate profit clearly illustrates the difference between established, profitable businesses and science-intensive companies investing in the future of medicine.
Employees in the company, segment and market as a whole
Number of employees in the company VSTM
For the biopharmaceutical company Verastem, this chart is a critical indicator in clinical development. An increase in this indicator often signifies that its lead drug candidates are successfully advancing into later, larger, and more resource-intensive phases of clinical trials, bringing the company closer to potential commercial success.
Share of the company's employees VSTM within the market segment - Oncology targeted therapy
Verastem, Inc. is a biotech company focused on developing targeted therapies for cancer. In this field, a team of several dozen brilliant scientists can be worth more than an entire factory. This chart allows us to estimate the share of talent in the narrow field of oncology that Verastem attracts and understand its importance as a center of research and development.
Number of employees in the market segment - Oncology targeted therapy
Verastem, Inc. is a biotechnology company focused on developing drugs to treat cancer by inhibiting key signaling pathways. Changes in the size of its scientific and clinical teams, visible in the graph, reflect the stages of drug development. Accelerated hiring often signals encouraging research results.
Number of employees in the market as a whole
Verastem, Inc. is a biotech company focused on cancer treatment. Its market capitalization depends on the success of clinical trials, not on the labor market, as shown in this chart. The need for new oncology drugs is enormous and unaffected by economic cycles, making its business unaffected by the overall market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company VSTM (VSTM)
Verastem, Inc. is a biotech company focused on oncology. Its market capitalization reflects investors' bet on the success of its scientific research. This chart clearly demonstrates how the market values intellectual capital in biotech. The company's entire value is attributed to its small team of scientists, leading to a very high cost per employee.
%20of%20the%20company%20VSTM%20(VSTM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-VSTM-VSTM&v=1772440687853 "Chart of market capitalization per employee (in thousands of dollars) of the company VSTM (VSTM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Verastem, Inc. is a biotech company focused on cancer drug development. Its value lies in the potential of its investigational drugs and the strength of its scientific team, not in its manufacturing capacity. This chart illustrates how investors value the company's intellectual capital per team member.
%20by%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-targeted-therapy&v=1772440687854 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology targeted therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Verastem is a biopharmaceutical company focused on developing cancer drugs. Its value is determined by the success of clinical trials. The chart illustrates the biotech startup's valuation. It shows how the market values a potential breakthrough in oncology treatment that could be achieved by a small but highly qualified team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772440687856 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company VSTM (VSTM)
Verastem is a biopharmaceutical company focused on oncology. They develop targeted drugs for cancer treatment. Like many biotechs in the R&D stage, this graph likely shows a negative value. It measures the investment (loss) per employee. This is the cost of funding high-risk but potentially breakthrough cancer research.
%20Chart%20VSTM%20(VSTM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-VSTM-VSTM&v=1772440687859 "Company Profit Per Employee (in thousands of dollars) Chart VSTM (VSTM)")
Profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Verastem (VSTM) is an R&D biotech (oncology). This chart shows the benchmark for "Oncology" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-targeted-therapy&v=1772440687861 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Verastem (VSTM) is a biopharmaceutical company focused on oncology, specifically the development of RAS/MAPK inhibitors. The company is in the R&D and clinical trials phase, meaning it is not profitable. This chart shows the investment (loss) per scientist working on the development of next-generation cancer drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772440687863 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee VSTM (VSTM)
Verastem is developing targeted therapies for cancer treatment. For a biotech company, this graph reflects progress in commercializing its research. Increased revenue per employee typically results from strategic partnerships and development fees, which validate the value of its intellectual property.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-VSTM-VSTM&v=1772440687864 "Sales chart per company employee VSTM (VSTM)")
Sales per employee in the market segment - Oncology targeted therapy
Verastem (VSTM) is an oncology company in the development and commercialization stage. They focus on innovative cancer treatments. This chart reflects their current phase. If the company is just launching a product, revenue per employee may be low, as the sales team is already hired and sales are just gaining momentum.
Sales per employee for the market as a whole
Verastem is a biotech company focused on targeted cancer therapy. This chart reflects their trajectory. During the clinical trial phase, revenue is minimal, but the R&D team is large. This metric is important as a future indicator: if the drug is successful and approved, it will show how effectively the company will be able to commercialize its research.
Short shares by company, segment and market as a whole
Shares shorted by company VSTM (VSTM)
Verastem (VSTM) is a biotech company focused on developing cancer drugs. Their approach involves inhibitors of signaling pathways (such as RAF/MEK) that are critical for the growth of certain tumors. This chart shows bearish bets. Skeptics might doubt the success of their clinical trials or whether their drugs will be competitive with existing ones.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-VSTM-VSTM&v=1772440687868 "Short Shares Chart for the Company VSTM (VSTM)")
Shares shorted by market segment - Oncology targeted therapy
Verastem (VSTM) is a biotech company focused on developing cancer treatments (RAF/MEK inhibitors), particularly for difficult-to-treat tumors. This chart is a barometer of sentiment across the entire biotech industry. If investors are shorting the sector, they don't believe risky R&D will succeed. For Verastem, which relies on capital, this signals a "venture drought."
Shares shorted by the overall market
Verastem (VSTM) is a biotech company focused on developing targeted therapies for cancer (RAF/MEK inhibitors). This chart measures overall market pessimism. When investors are fearful (the indicator rises), they flee en masse from speculative biotechs without profits, fearing that the company will need cash in poor market conditions to continue research.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator VSTM (VSTM)
Verastem is a biotech focused on oncology, specifically RAF/MEK inhibitors. This is a high-risk bet on their R&D platform. This chart measures the extremes of speculative sentiment. It shows when the stock is "overbought" on positive data or "oversold" on news of delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-VSTM-VSTM&v=1772440687873 "RSI 14 indicator chart for the company's stock VSTM (VSTM)")
RSI 14 Market Segment - Oncology targeted therapy
Verastem is an oncology company specializing in the development of cancer treatments (inhibitors) that block key signaling pathways that promote tumor survival. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire segment is overheated by speculative expectations of clinical success.
RSI 14 for the overall market
Verastem (VSTM) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VSTM (VSTM)
Verastem is a biotech company focused on developing targeted therapies for cancer, specifically drugs targeting the KRAS signaling pathway. This chart shows the average target price. Analysts' forecasts are based on clinical data and the potential success of their drugs in difficult-to-treat cancers.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VSTM-VSTM&v=1772440687879 "A chart showing analyst consensus forecasts for the expected stock price. VSTM (VSTM)")
The difference between the consensus estimate and the actual stock price VSTM (VSTM)
Verastem is a biotech company focused on oncology. They develop targeted cancer therapies (RAF/MEK inhibitors) that attack specific mutations in tumors. This chart reflects analysts' speculative expectations regarding their clinical data and the potential of their lead drug candidate.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VSTM-VSTM&v=1772440687880 "A chart showing the difference between the consensus forecast and the actual stock price. VSTM (VSTM)")
Analyst consensus forecast for stock prices by market segment - Oncology targeted therapy
Verastem is an oncology company developing innovative drugs for the treatment of difficult-to-treat cancers (low-grade serous ovarian carcinoma). This chart shows general expectations for the targeted oncology sector. It reflects whether experts believe in breakthroughs in the treatment of niche oncologies.
Analysts' consensus forecast for the overall market share price
Verastem is a biotech company specializing in developing drugs to treat difficult-to-treat cancers (such as ovarian and pancreatic cancer). This chart shows overall market risk appetite. For Verastem, as a clinical-stage company, overall market optimism (risk appetite) is critical to raising the capital needed to conduct late-stage trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index VSTM
Verastem is a biotech company focused on developing targeted cancer therapies. They specialize in signaling pathways (RAF/MEK), which are key drivers of tumor growth. This graph is a pure assessment of their R&D pipeline. Its dynamics depend entirely on their progress in clinical trials and the market's confidence in their scientific approach.
AKIMA Market Segment Index - Oncology targeted therapy
Verastem (VSTM) is a clinical-stage biotech focused on oncology; the company develops innovative drugs (RAS/MAPK inhibitors) for the treatment of difficult-to-treat cancers (ovarian and pancreatic). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this R&D focus on cancer (VSTM) differentiate it from the average pharma company?
The AKIM Index for the overall market
Verastem Oncology is a biotech company developing novel cancer treatments targeting the RAS pathway (ovarian and lung cancer). This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for assessing how the market perceives the clinical risks of this company.
